New drug combo shows promise for rare lung cancer mutation
NCT ID NCT06083857
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial is testing whether combining two drugs, amivantamab and tepotinib, can help control non-small cell lung cancer with MET alterations. Only 3 adults with advanced disease that cannot be surgically removed are enrolled. The main goal is to check safety and see if the combination works.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
amivantamab and tepotinib
What this could lead to
If it works, this could point toward a new treatment option for people with MET-altered non-small cell lung cancer.
What could go wrong
This is a very early, small trial with only 3 participants, so results may not apply to a larger population. The combination may cause side effects or fail to control the cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL-CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States